(Q46712950)

24 December 2017

title

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors (English)

1 reference

24 December 2017

1 reference

1 reference

Felix Bokstein

1

1 reference

24 December 2017

Shulim Shpigel

series ordinal

2

1 reference

24 December 2017

Deborah T Blumenthal

series ordinal

3

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

112

1 reference

24 December 2017

issue

10

1 reference

24 December 2017

page(s)

2267-2273

1 reference

24 December 2017

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Response of glioblastomas to EGFR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23401

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.23401

1 reference

24 December 2017

1 reference

24 December 2017